Former Madrigal exec sues, alleging retaliation after flagging safety concerns on approved MASH drug
A former senior vice president of clinical development at Madrigal Pharmaceuticals, Michael Charlton, has filed a federal lawsuit claiming he was forced to resign after raising internal safety concerns about the company’s approved medication for MASH.
The complaint, filed on Oct 9 in the Northern District of Illinois, alleges retaliation in violation of federal whistleblower‑protection statutes and seeks reinstatement or monetary damages.
Madrigal has vigorously denied the allegations, defending the safety profile of the drug and rejecting any suggestion of a cover‑up.
The lawsuit underscores ongoing tensions over drug safety oversight and may prompt further regulatory attention to the product.
This writeup was produced by pharmadog from original reporting by STAT.
Original headline: “STAT+: Former Madrigal Pharmaceuticals executive alleges coverup of safety issues tied to its drug”
read at STAT ↗
comments(0)
5-min edit window · permanent after that